MedTrace Logo

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

NCT04686682 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2026-01-09

No results posted yet for this study

Summary

This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study.

These two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.

Conditions

Interventions

DRUG

JAB-8263

Variable dose, orally Q2D with 28 days each cycle

DRUG

JAB-8263

RP2D dose, orally Q2D with 28 days each cycle

Sponsors & Collaborators

  • Jacobio Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jacobio Pharmaceuticals · Jacobio Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-07
Primary Completion
2028-01-31
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04686682 on ClinicalTrials.gov